HIV RNA monitoring is not available in most antiretroviral treatment (ART) programs in sub-Saharan Africa; switch to second-line therapy is mostly guided by clinical/immunological criteria. This may lead to unnecessary disease progression and drug resistance accumulation. We investigated the prognostic value of virological and immunological status 6 months after ART initiation with respect to death, loss to follow-up, and treatment switch
Two-thirds of the world's HIV-infected people live in sub-Saharan Africa, and more than 1.5 million ...
Background. Antiretroviral treatment programs in sub-Saharan Africa have high rates of early mortali...
Evaluation of antiretroviral treatment (ART) programmes in sub-Saharan Africa is difficult because m...
HIV RNA monitoring is not available in most antiretroviral treatment (ART) programs in sub-Saharan A...
ObjectiveRoutine monitoring of plasma HIV RNA among HIV-infected patients on antiretroviral therapy ...
Limited information exists on long-term prognosis of patients with sustained virologic response to a...
Background: The prognostic value of discordant immunologic (CD4 cell increase) and virologic (plasma...
BACKGROUND: Limited information exists on long-term prognosis of patients with sustained virologic r...
CD4 cell count and plasma viral load are well known predictors of AIDS and mortality in HIV-1-infect...
Improved survival among HIV-infected individuals on antiretroviral therapy (ART) has focused attenti...
Objectives: We assessed mortality associated with immunologic and virologic patterns of response at ...
In sub-Saharan Africa, early mortality is high following initiation of antiretroviral therapy (ART)....
Background. Viral load (VL) monitoring is standard of care in HIV-infected persons initiated on anti...
Human immunodeficiency virus (HIV) viremia was evaluated in 73 patients with long-standing infection...
Background. Antiretroviral treatment programs in sub-Saharan Africa have high rates of early mortali...
Two-thirds of the world's HIV-infected people live in sub-Saharan Africa, and more than 1.5 million ...
Background. Antiretroviral treatment programs in sub-Saharan Africa have high rates of early mortali...
Evaluation of antiretroviral treatment (ART) programmes in sub-Saharan Africa is difficult because m...
HIV RNA monitoring is not available in most antiretroviral treatment (ART) programs in sub-Saharan A...
ObjectiveRoutine monitoring of plasma HIV RNA among HIV-infected patients on antiretroviral therapy ...
Limited information exists on long-term prognosis of patients with sustained virologic response to a...
Background: The prognostic value of discordant immunologic (CD4 cell increase) and virologic (plasma...
BACKGROUND: Limited information exists on long-term prognosis of patients with sustained virologic r...
CD4 cell count and plasma viral load are well known predictors of AIDS and mortality in HIV-1-infect...
Improved survival among HIV-infected individuals on antiretroviral therapy (ART) has focused attenti...
Objectives: We assessed mortality associated with immunologic and virologic patterns of response at ...
In sub-Saharan Africa, early mortality is high following initiation of antiretroviral therapy (ART)....
Background. Viral load (VL) monitoring is standard of care in HIV-infected persons initiated on anti...
Human immunodeficiency virus (HIV) viremia was evaluated in 73 patients with long-standing infection...
Background. Antiretroviral treatment programs in sub-Saharan Africa have high rates of early mortali...
Two-thirds of the world's HIV-infected people live in sub-Saharan Africa, and more than 1.5 million ...
Background. Antiretroviral treatment programs in sub-Saharan Africa have high rates of early mortali...
Evaluation of antiretroviral treatment (ART) programmes in sub-Saharan Africa is difficult because m...